Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorotriphenylmethane SCHEMBL27845684 | 0.87 | TSHR (0.61) | TSHRCYP1A2KCNN4ALDH1A1CYP19A1 | |
| SCHEMBL8309862 | 0.85 | TSHR (0.48) | TSHRCYP1A2KCNN4ALDH1A1MAPK1 | |
| Chlorotriphenylmethane SCHEMBL461 | 0.84 | TSHR (0.65) | TSHRCYP1A2KCNN4ALDH1A1CYP19A1 | |
| Chlorotriphenylmethane SCHEMBL16781670 | 0.84 | TSHR (0.65) | TSHRCYP1A2KCNN4ALDH1A1CYP19A1 | |
| Chlorotriphenylmethane SCHEMBL7246540 | 0.81 | TSHR (0.61) | TSHRCYP1A2KCNN4ALDH1A1CYP19A1 | |
| Chlorotriphenylmethane SCHEMBL113884 | 0.81 | TSHR (0.61) | TSHRCYP1A2KCNN4ALDH1A1CYP19A1 | |
| Chlorotriphenylmethane SCHEMBL29446246 | 0.81 | TSHR (0.61) | TSHRCYP1A2KCNN4ALDH1A1CYP19A1 | |
| Chlorotriphenylmethane SCHEMBL11237663 | 0.81 | TSHR (0.61) | TSHRCYP1A2KCNN4ALDH1A1CYP19A1 | |
| Chlorotriphenylmethane SCHEMBL7567317 | 0.81 | TSHR (0.61) | TSHRCYP1A2KCNN4ALDH1A1CYP19A1 | |
| Chlorotriphenylmethane SCHEMBL28253307 | 0.81 | TSHR (0.61) | TSHRCYP1A2KCNN4ALDH1A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4790179-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| US-20090306030-A1 | Methods Of Inhibiting Osteoclast Activity | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-12-10 | — | — | US | claimed |
| EP-1207873-A4 | METHODS OF INHIBITING OSTEOCLAST ACTIVITY | UNIV PENNSYLVANIA (US) | 2006-04-12 | — | — | EP | claimed |
| US-20050080133-A1 | Methods of inhibiting osteoclast activity | GREENE MARK I (US) | 2005-04-14 | — | — | US | claimed |
| JP-2003505503-A | — | — | 2003-02-12 | — | — | JP | claimed |
| EP-1207873-A1 | METHODS OF INHIBITING OSTEOCLAST ACTIVITY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2002-05-29 | — | — | EP | claimed |
| WO-2001008677-A1 | METHODS OF INHIBITING OSTEOCLAST ACTIVITY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2001-02-08 | — | — | WO | claimed |
| US-8785419-B2 | Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-07-22 | — | — | US | disclosed |
| US-8019557-B2 | Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-09-13 | — | — | US | disclosed |
| US-8003628-B2 | Methods of inhibiting osteoclast activity | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2196930-B1 | Cavity induced allosteric modificatin of intermolecular interactions and methods of identifiying compounds that effect the same | UNIV PENNSYLVANIA (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100151507-A1 | Cavity Induced Allosteric Modification Of Intermolecular Interactions And Methods Of Identifying Compounds That Effect The Same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-17 | — | — | US | disclosed |
| EP-2196930-A1 | Cavity induced allosteric modificatin of intermolecular interactions and methods of identifiying compounds that effect the same | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-06-16 | — | — | EP | disclosed |
| EP-1091974-A4 | CAVITY INDUCED ALLOSTERIC MODIFICATION OF INTERMOLECULAR INTERACTIONS AND METHODS OF IDENTIFYING COMPOUNDS THAT EFFECT THE SAME | UNIV PENNSYLVANIA (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050080133-A1 | Methods of inhibiting osteoclast activity | GREENE MARK I (US) | 2005-04-14 | — | — | US | disclosed |
| US-6673771-B1 | ADMINISTERING INHIBITOR OF TUMOR NECROSIS FACTOR RELATED ACTIVATOR INDUCED CYTOKINE/RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA BETA LIGAND, PEPTIDE HAVING CYCLIC PORTION AND EXOCYCLIC PORTIONS COMPRISING TYROSINE OR PHENYLALANINE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2004-01-06 | — | — | US | disclosed |
| EP-1207873-A1 | METHODS OF INHIBITING OSTEOCLAST ACTIVITY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-1091974-A2 | CAVITY INDUCED ALLOSTERIC MODIFICATION OF INTERMOLECULAR INTERACTIONS AND METHODS OF IDENTIFYING COMPOUNDS THAT EFFECT THE SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2001008677-A1 | METHODS OF INHIBITING OSTEOCLAST ACTIVITY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000001349-A2 | CAVITY INDUCED ALLOSTERIC MODIFICATION OF INTERMOLECULAR INTERACTIONS AND METHODS OF IDENTIFYING COMPOUNDS THAT EFFECT THE SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306030-A1 | Methods Of Inhibiting Osteoclast Activity | NFATC1, CD40LG, CD14 | TSHR 753/4885CYP1A2 4582/4885KCNN4 4472/4885 |
| US-20050080133-A1 | Methods of inhibiting osteoclast activity | NFATC1, CD40LG, CD14 | TSHR 753/4885CYP1A2 4582/4885KCNN4 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.